Skip to main content

Table 1 HPV prevalence detected by the RT hrHPV test and the HC2 test in comparison to the liquid based cytology (LBC) results

From: Study-based evaluation of the Abbott RealTime High Risk HPV test in comparison to the HC2 HR HPV test in women aged ≥30 years using residual LBC ThinPrep specimens

LBC RT + ve % (95 % CI) HR HC2 + ve % (95 % CI) κ (95 % CI)
Normal (Pap I/II) 5.4 % (4.2-6.9) 5.6 % (4.3-7.1) 0.78 (0.69-0.87)
ASC-US (Pap IIw) 21.4 % (12.7-33.8) 28.6 % (18.4-41.5) 0.62 (0.38-0.86)
ASC-H, AGC (Pap III) 50.0 % (28.0–72.0) 50.0 % (28.0–72.0) 1 (1.0–1.0)
LSIL, HSIL (Pap IIID) 65.1 % (59.6–70.3) 72.1 % (66.8–76.9) 0.76 (0.68–0.84)
HSIL, CIS (Pap IVa) 94.7 % (82.7–98.6) 100 % (90.8–100) 1
HSIL, CIS, Micro (IVb) 100 % (34.2–100) 100 % (34.2–100) 1
Micro, Invasive (PapV) 100 % (20.6–100) 100 % (20.6–100) 1
HSIL+ (≥Pap IVa) 95.1 % (83.9–98.7) 100 % (91.4–100) 1
AGC+ (≥Pap III) 68.0 % (62.9–72.5) 74.3 % (69.5–78.6) 0.78 (0.70–0.84)
Overall 21.4 % (19.3–23.5) 23.4 % (21.3–25.6) 0.87 (0.84–0.90)
  1. +ve: positive; −ve: negative; +: and worse
  2. 95 % CI for HPV prevalence were calculated using the Wilson Score method